LEXICON PHARMACEUTICALS Business Summary

Lexicon Pharmaceuticals, Inc. (LXRX) is a commercial-stage biopharmaceutical company that generates revenue through direct product sales, strategic licensing, and milestone-based partnerships. Its primary business segments focus on the discovery and commercialization of treatments for cardiometabolic diseases and neuropathic pain, centered on its lead product, INPEFA (sotagliflozin), which is approved for heart failure. The company’s financial model is increasingly driven by high-margin licensing, including a billion-dollar global agreement with Novo Nordisk for its obesity candidate LX9851 and a partnership with Viatris for international distribution. Lexicon competes directly with major pharmaceutical players in the SGLT inhibitor market, such as AstraZeneca (Farxiga), Eli Lilly/Boehringer Ingelheim (Jardiance), and Johnson & Johnson (Invokana). As a specialized biotech, Lexicon differentiates itself by utilizing a dual SGLT1 and SGLT2 inhibition mechanism, positioning it as a niche innovator targeting high-need cardiovascular and diabetic indications where large-cap incumbents dominate. The company is led by Chief Executive Officer Dr. Michael Exton, who joined in 2024 after a 14-year tenure at Novartis, where he served as the Global Head of the Cardiovascular, Renal, and Metabolism franchise. Supporting him is President and COO Jeffrey L. Wade, a veteran executive with over two decades at the firm, and CFO Scott Coiante. Lexicon was co-founded by Dr. Arthur T. Sands, who pioneered the company’s high-throughput gene knockout platform to identify novel therapeutic targets. Celebrating its 30th anniversary in 2026, the company maintains a strong institutional backing, with Artal Group S.A. (Invus) holding a significant majority stake of approximately 47%, providing stable long-term capital. Other notable board members and investors include representatives from major financial institutions like Vanguard and BlackRock, reflecting robust interest in the company’s 2026 milestones, which include the planned resubmission of Zynquista for type 1 diabetes and Phase 3 readouts in hypertrophic cardiomyopathy.